Targets › IL25
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Jun 2028.
Cytokine produced by various cells such as eosinophils, T-helper type 2 (Th2) cells or epithelial cells that plays a role in internal safety of adaptive immune responses by regulating cytokine production. Promotes and augments T-helper type 2 responses locally or systemically. (UniProt, Q9H293)
Open in Phaseline: the race on IL25, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bionyra Pharma | BYN-001 humanized IgG1 monoclonal antibody targeting IL-25 | IL25 | Phase 1 | Atopic Dermatitis | Jun 2028 |
Atopic Dermatitis (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.